These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Bishydroxycoumarin (Dicumarol) prophylaxis. Use in the prevention of postoperative thromboembolic complications in surgical patients. MILCH E; BERMAN L; EGAN RW Arch Surg; 1961 Sep; 83():444-7. PubMed ID: 13770596 [No Abstract] [Full Text] [Related]
5. Clinical experiences with anticoagulants; a comparison of coumadin (warfarin) sodium and dicumarol (bishydroxycoumarin). NICHOLSON JH Angiology; 1957 Oct; 8(5):456-65. PubMed ID: 13478915 [No Abstract] [Full Text] [Related]
6. [Plasmin (fibrinolysin) infusions]. ROSOLLECK H Med Welt; 1961 Oct; 41():2114-8. PubMed ID: 14494137 [No Abstract] [Full Text] [Related]
7. The present status of anticoagulants in thrombo-embolic disease. MILLS ES Can Med Assoc J; 1953 Jan; 68(1):6-9. PubMed ID: 13019701 [No Abstract] [Full Text] [Related]
8. The present status of the clinical evaluation of fibrinolysin. CHAPPLE RV; SINGHER HO Can Med Assoc J; 1959 Aug; 81(4):231-4. PubMed ID: 13809263 [No Abstract] [Full Text] [Related]
9. Administration of Dicoumarol and Marcoumar during operation to prevent postoperative thrombo-embolic complications in patients over 50 years of age. STORM O; AAGAARD P; LINDENBERG J; DONS N Acta Chir Scand Suppl; 1961; Suppl 283():307-14. PubMed ID: 13917524 [No Abstract] [Full Text] [Related]
10. Studies of the plasmin-plasminogen system in thromboembolic diseases; its modifications by thrombolysin therapy. TSITOURIS G; SANDBERG H; DELEON AC; LECKS L; BELLET S Am J Cardiol; 1960 May; 5():680-7. PubMed ID: 13839651 [No Abstract] [Full Text] [Related]
11. FIBRINOLYSIN TREATMENT OF THROMBOEMBOLISM. ISRAEL HL; FISHER GR; MUELLER O; COOPER DA JAMA; 1964 May; 188():628-31. PubMed ID: 14121282 [No Abstract] [Full Text] [Related]
12. Treatment of thrombo-embolism with anticoagulants. PALOS LA Ther Hung; 1960; 8(3-4)():18-23. PubMed ID: 14483440 [No Abstract] [Full Text] [Related]
14. [FIBRINOLYSIN, a new agent against thromboembolic disease]. Prod Pharm; 1959 Sep; 14():502. PubMed ID: 13858182 [No Abstract] [Full Text] [Related]
15. The treatment of some problem cases of thromboembolic disease with fibrinolysin. HARLOE JP Angiology; 1959 Aug; 10():283-91. PubMed ID: 14399834 [No Abstract] [Full Text] [Related]
16. Human fibrinolysin in the treatment of acute thromboembolic disease. ANLYAN WG; WOODHALL B; STICKEL D; MAHALEY MS Bull Soc Int Chir; 1962; 21():273-7. PubMed ID: 13861677 [No Abstract] [Full Text] [Related]
17. A comparative evaluation of tromexan and dicumarol in the treatment of thromboembolic conditions--based on experience with 514 patients; a report of the Committee on Anticoagulants of the American Heart Association. SCARRONE LA; BECK DF; WRIGHT IS Circulation; 1952 Oct; 6(4):489-514. PubMed ID: 12979062 [No Abstract] [Full Text] [Related]
18. Fibrinolysin as an agent for treatment of thromboembolic accidents. CLIFFTON EE JAMA; 1961 Jan; 175():302-6. PubMed ID: 13694109 [No Abstract] [Full Text] [Related]
19. Dose response curves with varying doses of fibrinolysin. WILSON WL; NASO F; LIPPMANN E Am J Cardiol; 1960 Aug; 6():503-6. PubMed ID: 13845148 [No Abstract] [Full Text] [Related]
20. Prophylaxis and therapy of thromboembolism with anticoagulants. FRYD CH; DE VRIES A; GITELSON S; GALEWSKI K; HEIMAN-HOLLAENDER E Acta Med Orient; 1950 May; 9(5):105-22. PubMed ID: 24537757 [No Abstract] [Full Text] [Related] [Next] [New Search]